BioXcel (BTAI) Insider Filing: Mehta Adds Shares via RSU Vesting
Rhea-AI Filing Summary
BioXcel Therapeutics insider activity: Vimal Mehta, CEO and President and a director, reported two small acquisitions of common stock and corresponding restricted stock units in mid-September 2025. On 09/14/2025 he received 163 RSUs (vesting contingent) and 163 shares were recorded as acquired; on 09/15/2025 he received 219 RSUs and 219 shares were recorded as acquired. Following these transactions Mr. Mehta directly beneficially owned 20,493 shares. He also discloses indirect ownership of 480,343 shares held of record by BioXcel LLC, of which he is a manager, and one shareholding is reported as held by spouse.
Positive
- Scheduled RSU vesting and acquisition disclosed (163 shares on 09/14/2025 and 219 shares on 09/15/2025), showing ongoing executive equity alignment
- Clear disclosure of indirect holdings of 480,343 shares held by BioXcel LLC with an explicit disclaimer regarding beneficial ownership
Negative
- None.
Insights
TL;DR: Routine executive vesting and small open-market acquisitions; limited investor impact.
These filings reflect scheduled vesting and small purchases rather than opportunistic trading. The reported direct increases of 163 and 219 shares are minor relative to the 480,343 shares held indirectly by BioXcel LLC. There is no new debt, dilution event, or sale reported. For valuation or market-impact analysis these transactions are immaterial on their own but confirm continued executive ownership alignment with the company.
TL;DR: Disclosure demonstrates customary reporting of vested RSUs and indirect holdings via related entities.
The report properly discloses RSU vesting and beneficial ownership through BioXcel LLC with a formal disclaimer of direct beneficial ownership beyond pecuniary interest. The separate reporting of direct and indirect holdings and the attorney-in-fact signature meet Section 16 filing norms. No governance concern or unexpected change in control is evident from the filing text alone.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 219 | $0.00 | -- |
| Exercise | Common Stock | 219 | $0.00 | -- |
| Exercise | Restricted Stock Units | 163 | $0.00 | -- |
| Exercise | Common Stock | 163 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose. On March 14, 2022, the Reporting Person was granted 2,609 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
